Biocompatibility assessment of silk nanoparticles : hemocompatibility and internalization by human blood cells

Maitz, Manfred F. and Sperling, Claudia and Wongpinyochit, Thidarat and Herklotz, Manuela and Werner, Carsten and Seib, F. Philipp (2017) Biocompatibility assessment of silk nanoparticles : hemocompatibility and internalization by human blood cells. Nanomedicine: Nanotechnology, Biology and Medicine, 13 (8). pp. 2633-2642. ISSN 1549-9634

[img]
Preview
Text (Maitz-etal-NNBM-2017-assessment-of-silk-nanoparticles-hemocompatibility-and-internalization-by-human-blood-cells)
Maitz_etal_NNBM_2017_assessment_of_silk_nanoparticles_hemocompatibility_and_internalization_by_human_blood_cells.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (1MB)| Preview

    Abstract

    Many nanoparticles are designed for use as potential nanomedicines for parenteral administration. However, emerging evidence suggests that hemocompatibility is important, but is highly particle- and test-bed dependent. Thus, knowledge of bulk material properties does not predict the hemocompatibility of uncharacterized nanoparticles, including silk nanoparticles. This study compares the hemocompatibility of silk versus silica nanoparticles, using whole human blood under quasi-static and flow conditions. Substantial hemocompatibility differences are noted for some nanoparticles in quasi-static versus dynamic studies; i.e., the inflammatory response to silk nanoparticles is significantly lower under flow versus quasi-static conditions. Silk nanoparticles also have very low coagulant properties - an observation that scales from the macro- to the nano-level. These nanoparticle hemocompatibility studies are complemented by preliminary live cell measurements to evaluate the endocytosis and trafficking of nanoparticles in human blood cells. Overall, this study demonstrates that nanoparticle hemocompatibility is affected by several factors, including the test bed design.